Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences declared a quarterly dividend on Wednesday, July 26th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share on Thursday, September 28th. This represents a $2.08 annualized dividend and a dividend yield of 2.77%. The ex-dividend date is Thursday, September 14th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings results on Wednesday, July, 26th. The company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts' expectations of $6.35 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. Gilead Sciences's revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period last year, the firm earned $3.08 EPS. View Gilead Sciences' Earnings History.

26 brokers have issued 12 month price targets for Gilead Sciences' stock. Their forecasts range from $65.50 to $95.00. On average, they anticipate Gilead Sciences' share price to reach $80.40 in the next twelve months. View Analyst Ratings for Gilead Sciences.

Here are some recent quotes from research analysts about Gilead Sciences stock:

• 1. According to Zacks Investment Research, "Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales." (7/18/2017)
• 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
• 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
• 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Gilead Sciences saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 13,658,785 shares, an increase of 15.7% from the June 15th total of 11,804,652 shares. Based on an average daily volume of 13,707,757 shares, the short-interest ratio is currently 1.0 days. Approximately 1.1% of the company's shares are short sold.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene Corporation (CELG), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO) and China Biologic Products (CBPO).

Gilead Sciences' management team includes the folowing people:

• John C. Martin Ph.D., Executive Chairman of the Board
• John F. Milligan Ph.D., Chief Executive Officer, Director
• Robin L. Washington, Chief Financial Officer, Executive Vice President
• Kevin B. Young, Chief Operating Officer
• Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
• James R. Meyers, Executive Vice President - Worldwide Commercial Operations
• John F. Cogan Jr. Ph.D., Lead Independent Director
• Kelly A. Kramer, Independent Director
• Kevin E. Lofton, Independent Director

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.42%), State Treasurer State of Michigan (0.24%), Swedbank (0.17%), Bessemer Group Inc. (0.14%), Great West Life Assurance Co. Can (0.14%) and Strs Ohio (0.11%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Bessemer Group Inc., APG Asset Management N.V., Rothschild Asset Management Inc., NN Investment Partners Holdings N.V., First Quadrant L P CA, Boston Advisors LLC, Parkwood LLC and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, ANTIPODES PARTNERS Ltd, Aperio Group LLC, Foundation Resource Management Inc., Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., US Bancorp DE and Boston Financial Mangement LLC. View Insider Buying and Selling for Gilead Sciences.

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Gilead Sciences stock can currently be purchased for approximately $74.96.